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Abstract 
 
Quantifying Neurological Risk Factors in Childhood Brain Tumor Treatment: 
Practical Scales for Predicting Neuropsychological Outcomes 
Mark David McCurdy 
Brian P. Daly, Ph.D. 
 
 
 
 
Background 
Childhood brain and central nervous system (CNS) tumors are the second most 
common form of pediatric malignancy. Tumor-directed therapies present a 
substantial risk to the developing nervous system placing survivors at risk for 
disruptions across multiple domains of cognitive and behavioral functioning, 
which are thought to be chronic in nature. Despite these findings, few objective 
measures have been developed to quantify the extent or intensity of exposure to 
tumor-related treatments or use this information to predict neuropsychological 
outcomes. The Neurological Predictor Scale (NPS) is designed to quantify 
treatment exposures and neurological comorbidities. Preliminary investigations 
suggested the scale’s utility in predicting global cognitive functioning, cognitive 
efficiency, and adaptive functioning in survivors several years post-treatment. The 
Pediatric Neuro-Oncology Rating of Treatment Intensity (PNORTI) is another 
clinician-generated scaled used to classify the intensity of pediatric brain tumor 
treatments. However, no studies to date have examined the utility of this measure 
in predicting subacute neuropsychological functioning in survivors of childhood 
brain tumor. 
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Aims 
The present study aimed to examine the influence of treatment intensity and 
treatment-related neurological comorbidities on subacute neuropsychological 
outcomes in survivors of childhood brain tumor. Specifically, this study sought to 
establish the utility of the NPS and PNORTI in predicting neuropsychological 
performance approximately nine months post-treatment conclusion. It was 
hypothesized that higher scores on each measure would predict worse 
performance across neuropsychological domains. Neurological sequelae captured 
by the NPS also were hypothesized to add incrementally to the prediction of 
subacute neuropsychological functioning when pooled with treatment intensity 
factors from the PNORTI. 
 
Methods 
Participants (N = 35) included youth (51.40% female) between the ages of 6 and 
15 years  (M = 11.00, SD = 2.71). Survivors were recruited from among patients 
transitioning off tumor-directed treatment for the management of their brain 
tumor at the Children’s Hospital of Philadelphia. Baseline measures were 
completed by consenting participants within 4-5 months following the cessation 
of treatment (Baseline) and again 6 (± 2) months later (Follow-up). At each 
timepoint, participants were administered measures of processing speed and 
working memory (WISC-IV), executive functioning (TEA-Ch), auditory verbal 
memory (WRAML-2), and caregiver-reported executive behavior (BRIEF) and 
adaptive functioning (BASC-2). Hierarchical multiple linear regressions, 
controlling for Baseline performance, were used to examine the predictive and 
incremental validity of both treatment-related risk scales. 
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Results 
NPS total scores ranged from 1 to 9 (M = 4.69, SD = 2.07) and PNORTI scores 
ranged from 1 (n = 6; 17.10%) to 2 (n = 29; 82.90%). Interrater reliability 
coefficients were excellent for the NPS (ICC = 0.97) and PNORTI (κ = .82). 
Hierarchical multiple regressions revealed that the NPS and PNORTI did not 
explain an additional amount of variance in processing speed, auditory attention, 
working memory, executive functioning, verbal memory, or adaptive skills above 
and beyond Baseline performance on these measures. Additionally, neurological 
comorbidities and risk factors did not incrementally improve the predictive utility 
of PNORTI treatment intensity scores for Follow-Up performance across 
measures. 
 
Discussion 
The present study provides the first examination of the, interrater reliability, and 
clinical utility of the NPS and PNORTI for predicting subacute 
neuropsychological functioning in a sample of childhood brain tumor survivors. 
The NPS and PNORTI can be readily and reliably generated by providers of 
differing training backgrounds familiar with neuro-oncology treatments. The 
subacute period may be premature’ for detecting neuropsychological late effects 
associated with treatment and neurological comorbidities in this population. 
Future research is needed to determine the predictive utility of these measures in 
long-term survivors, allowing providers to coordinate early intervention in the 
survivorship period. 
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Introduction 
Pediatric brain tumors are the second most common form of malignancy 
in childhood (Ries et al., 2002; American Cancer Society, 2016) and the leading 
cause of mortality in childhood cancer populations under the age of 15 
(Armstrong et al., 2009; Turner, Rey-Casserly, Liptak, & Chordas, 2009). Recent 
figures generated from the Central Brain Tumor Registry of the United States 
between 2004 and 2008 indicate an incidence rate of 5.05 new cases of pediatric 
brain tumor per 100,000 children (Dolecek at al., 2012). Fortunately, 
advancements in detection and treatment techniques for Central Nervous System 
(CNS) tumors have steadily reduced mortality rates over the past several decades 
(Kohler et al., 2011), with approximately 75% surviving beyond five years 
(Howlader et al., 2011) and 28% beyond ten years and into adulthood (Dolecek, 
Propp, Stroup, & Kruchko, 2012). Given this increase in long-term survival, more 
attention is now being directed towards the survivorship period and successful 
return to regular daily routines. While evidence suggests that tumor and disease 
factors may impact acute (i.e., during disease/treatment) and post-acute (i.e., 
immediately following treatment) neurocognitive functioning, very little research 
exists with respect to the subacute period (i.e., within the first year post-
treatment). 
Intact long-term neurocognitive functioning is critically important for 
quality of life outcomes as survivors transition off tumor-directed therapies. 
Unfortunately, neurological and neurophysiological side effects associated with 
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brain-based tumors and these advanced treatments position survivors at risk for 
protracted adverse neuropsychological outcomes, often referred to as 
neurocognitive ‘late effects’ (Gragert & Ris, 2011; Turner et al., 2009). These 
deleterious effects typically emerge within the first year following tumor-directed 
treatments and may be chronic in nature (Maddrey et al., 2005), contributing to 
significant morbidity in functional and quality of life domains for survivors and 
their families (Hocking et al., 2011; Robinson et al., 2010). 
While global intellectual outcomes have been the focus of most research, 
literature is now emerging which suggests survivors may experience deficits 
along a variety of neurocognitive domains including global intellectual 
functioning, attention, working memory, psychomotor speed, processing speed, 
executive, and academic skills (Mulhern & Butler, 2004; Mulhern, Merchant, 
Gajjar, Reddick, & Kun, 2004; Palmer et al., 2013). A recent meta-analysis 
conducted by Robinson et al. (2010) integrates the late effects literature on 
pediatric brain tumor survivors. Findings indicate that when brain tumor survivors 
were compared to normative data, small to large effect sizes emerged across 
several neurocognitive domains including global IQ (g = -0.83), academic 
achievement (gs = -0.45 – -0.63), attention (g = -1.22), psychomotor skills (g = -
1.43), visuospatial skills (g = -1.14), verbal memory (g = -1.14), and language (g 
= -0.93). Parent-reported attention problems have also been shown to predict later 
adaptive dysfunction in this population (Papazoglou, King, Morris, & Krawiecki, 
2009). In light of this emerging evidence, treatment techniques are now evaluated 
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not only in terms of maintaining long-term survival rates, but also for their ability 
to limit secondary neurocognitive morbidity. 
CNS neoplasms classified according to the World Health Organization 
(WHO) grading system consist of four categories related to prognosis: slow-
growing nonmalignant tumors (Grade I), slow-growing tumors that may or may 
not be malignant (Grade II), malignant tumors that often recur as higher grade 
tumors (Grade III), and malignant tumors that undergo rapid cell differentiation 
(Grade IV; CDC, 2004). Higher grade tumors are often approached with more 
aggressive treatments (discussed below). Tumors are further classified by location 
(i.e., supratentorial vs. infratentorial vs. sellar) and affected cell type (i.e., 
neuroepithelial tissue vs. other CNS tumors); childhood brain tumors commonly 
arise in the cerebellum (16.3%), pituitary (13.5%), brain stem (10.4%), ventricles 
(5.8%), or cerebrum (5.5%), with the broad category of ‘glioma’ accounting for 
53% and 36% of children ages 0-14 years and 15-19 years, respectively (Ostrom 
et al., 2013).  Though brain tumors technically only include neoplasms arising 
from neuroepithelial tissue (e.g., neural, glial, and ependymal cells), tumors 
arising from cranial nerves, meningeal or vascular tissue are often treated with 
comparable methods. 
Treatments for pediatric brain tumors typically involve a multimodal 
approach consisting of a combination of surgical resection, chemotherapy, and/or 
radiation therapy. Decisions regarding the method, timing, and intensity of these 
treatments depend on a host of tumor-related (i.e., tumor location, histology) and 
patient demographic factors (i.e., age). Because brain tumors are heterogeneous in 
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terms of histology and location, and therapeutic interventions vary according to 
these factors, there is no all-inclusive endophenotype that characterizes 
neuropsychological outcome in survivors (Gragert & Ris, 2011). However, 
research over the past several decades has continued to document the 
neurocognitive risk posed by the management of these lesions. There is also a 
growing need for refined methods for predicting neuropsychological status in 
survivors following treatment for childhood brain tumors. Importantly, such 
methods must possess clinical utility and be generated with relative efficiency as 
practitioners plan neurorehabilitative efforts and accommodations. The following 
sections will 1) provide a review of modern treatment modalities, 2) overview 
their associations with later neuropsychological functioning, and 3) discuss the 
development and application of measures designed to quantify risk for 
neurocognitive late effects. 
 
Treatment Modalities & Neurophysiological Effects 
Surgical Resection. Though the decision to proceed with neurosurgical 
removal of a child’s brain tumor depends on various neuroanatomical factors, 
where possible, resection is typically the first line of treatment for CNS-based 
neoplasms. Particularly, superficially-located tumors which are most accessible to 
the neurosurgical team and tumors that are well circumscribed without extensive 
vascular involvement present the most favorable prognosis given the relative ease 
in which total resection is possible (Pollack, 2011). Various tumor-directed 
surgical intervention strategies may be attempted, ranging from 100% removal of 
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the macroscopic tumor mass (gross total resection), through subtotal and partial 
resection, often referred to as tumor ‘de-bulking’. Tumor biopsy is performed to 
determine tumor histology and/or to confirm diagnosis. This biopsy is thought to 
only be associated with acute neurological sequelae and not significantly 
impactful of subacute cognition. Research has consistently demonstrated that 
gross total resection, rather than subtotal or partial resections, is associated with 
the most favorable prognosis in terms of progression free survival and overall 
survival in children (Kramm et al., 2006; Wisoff et al., 2011).  
However, the relationship between extent of resection and outcome is 
inextricably linked to tumor location – those tumors which are superficially 
located do not involve deeper brain structures such as the basal ganglia and 
brainstem, which make them more amenable to removal without associated 
complications and secondary neurological morbidity (Pollack, 2011). Resection 
alone (i.e., in the absence of radiation exposure and chemotherapy) may also 
contribute to diminished white matter integrity, presumably due to alterations in 
cerebral blood flow to more anterior brain regions (Soelva et al., 2013). 
Neurosurgical intervention has also been linked to reduced intellectual ability 
(Kao et al., 1994), deficits in attention, processing speed, and memory (Steinlin et 
al., 2003), and adverse neurological sequelae (Sønderkær et al., 2003). 
Radiation Therapy. In conjunction with surgical resection, children may 
also be treated with radiotherapy targeting the tumor and/or the entire craniospinal 
axis. Decisions regarding radiation dose and targets largely depend on tumor 
histology, size, location, and likelihood of metastasis/dissemination. ‘Standard-
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Risk’ tumors include those with <1.5cm2 of remaining tumor following surgery, 
or tumors with pathology that does not include risk of dissemination. Following 
surgical intervention, these tumors are often treated with focal radiotherapy and/or 
chemotherapy. Tumors deemed ‘High-Risk’ include those with >1.5cm2 residual 
tumor following surgical resection or risk of dissemination throughout the 
craniospinal axis. These children often receive high-dose radiation targeting the 
entire neuroaxis in order to combat disease spread. In children diagnosed before 
the age of 3, conventional photon radiotherapy is delayed as long as possible due 
to the profound impact that irradiation has on cognitive outcomes for these 
children (Bloom, Wallace, & Henk, 1969). Conventional radiotherapy, however, 
may be unavoidable and neurocognitive outcomes are poor for these children 
(Duffner et al., 1993). Protocols for these youngsters include a combination of 
extended high-dose chemotherapy and surgical resection. Treatment with proton-
beam radiotherapy in young children is also becoming more common (Merchant 
et al., 2008), and though clinical trials have yet to support their efficacy, 
preliminary evidence is promising (Merchant, 2013). 
Traditional therapeutic radiation deposits high-energy photons to tissue, 
ejecting electrons from atoms which disrupts various cellular components 
including the cell’s DNA (Hoffman & Yock, 2009). When targeting a non-
superficially-located tumor, the radiation path must pass through healthy tissue on 
its way to the tumor (entrance dose), deposit into the tumor itself, and continues to 
pass through healthy tissue beyond the tumor (exit dose). Importantly, radiation 
indiscriminately damages both tumor cells and healthy tissue at the same rate. 
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Even though healthy tissue has a more robust DNA repair capacity than cancer 
cells, as the radiation dose increases the extent of DNA damage increases making 
it more difficult for cells to be repaired (Hoffman & Yock, 2009). Fortunately, 
new techniques designed to limit the degree of damage to healthy neural tissue, 
including conformal and proton-beam radiotherapy, are becoming increasingly 
popular and show promise for reducing secondary neurocognitive morbidity 
(Merchant et al., 2008).  
Because myelination of developing axons is not complete until early 
adulthood (Barnea-Goraly et al., 2005), white matter is particularly vulnerable to 
the neurotoxic effects of radiotherapy. The relationship between total radiation 
dose, white matter volumes, and cognitive outcome is well established – 
particularly in younger children for whom radiation exposure has been shown to 
be the most damaging to brain development (Mulhern et al., 2001; Reddick et al., 
2005; Reddick et al., 2000). Mulhern et al. (1999) conducted a cross-sectional 
study comparing children treated for medulloblastoma receiving radiotherapy and 
children treated for low-grade gliomas of the posterior fossa who underwent 
neurosurgery in the absence of radiotherapy. Children who underwent 
radiotherapy demonstrated reduced white matter volumes, increased CSF 
volumes, and equal grey matter volumes compared to children treated with 
surgery alone – reflecting the particular vulnerability of white matter to radiation. 
Longitudinal studies have also demonstrated the effect of radiotherapy on 
developing white matter, suggesting a linear relationship with radiation dose. In 
one longitudinal study, children who received higher doses of radiotherapy (36gy) 
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had reduced white matter volumes compared to those who received lower-dose 
radiation (23.4gy; Reddick et al., 2000). Similar results have been found when 
specific white matter structures are examined (i.e., the corpus callosum;(Palmer et 
al., 2002). 
Chemotherapy. Some forms of pediatric brain tumors have been found to 
be chemoresponsive, and various chemotherapy agents are increasingly being 
utilized particularly in younger infants. For some tumor types, neo-adjuvant 
systemic chemotherapy is often used to supplement surgical resection and in place 
of more intensive radiotherapy regimens. As noted above, chemotherapy has 
shown promise in delaying the need to irradiate brain tumors in children under the 
age of three, for whom radiotherapy has been shown to be particularly toxic to 
developing white matter and deleterious to cognition (Duffner et al., 1993; 
Rutkowski et al., 2009; Strother et al., 2001). However, though the neurological 
effects of chemotherapy are more subtle than those produced by radiotherapy, 
chemotherapy is not without its own adverse neurophysiological consequences. 
Analyzing the unique influence of chemotherapy on the developing brain 
poses a challenge to researchers because chemotherapy is rarely, if ever, 
administered in isolation from other treatments in the management of solid 
tumors. Much of the research on the neurophysiological and neuropsychological 
effects of chemotherapy comes from studies of populations with acute 
lymphoblastic leukemia (ALL), treated intrathecally, or optic pathway gliomas, 
for whom radiotherapy is often not prescribed. From this literature, researchers 
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can better understand the unique impact that chemotherapy poses on the 
developing brain. 
High-dose chemotherapeutic regimens typically involve simultaneous 
administration of multiple agents. The most common chemotherapeutic agents for 
childhood brain tumors include cisplatin, vincristine, cyclophosphamide, 
etoposide, methotrexate, and carboplatin (Baron Nelson, Compton, Patel, Jacob, 
& Harper, 2013), which may be administered intravenously, intrathecally, or 
intraventricualarly. In addition to acute effects of chemotherapy which include 
seizures, headache, abnormal neurological signs, and nausea (Moleski, 2000), 
acute peripheral neuropathy (vincristine) and chronic hearing loss may result from 
the use of ototoxic platinum-based agents (e.g., cisplatin, carboplatin; Travis et 
al., 2014). There is also evidence to suggest that these chemotherapeutic agents 
exert neurotoxic effects to the developing CNS, including cortical atrophy, 
necrotizing leukoencephalopathy, subacute myeloencephalopathy, mineralizing 
angiopathy, and cerebellar sclerosis (Moleski, 2000). Methotrexate in particular 
has been implicated in the development of later leukoenchephalopathy (Riva et 
al., 2002), the extent of which has been shown to be related to intraventricular (r = 
.53), but not intraveneous dose (Rutkowski et al., 2005). 
Evidence from rodent models suggests that the developing brain may be 
more vulnerable to the neurotoxic effects of chemotherapy than adult brains 
(Rzeski et al., 2004). Specifically, chemotherapeutic agents including 
methotrexate may disrupt the genesis of neural progenitor cells in the developing 
hippocampus, which may in turn limit the development of cerebral white matter 
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and contribute to neurocognitive deficits in survivors (Dietrich, Monje, Wefel, & 
Meyers, 2008). Compared to healthy controls, patients treated for ALL with 
intrathecal chemotherapy in childhood evidence reductions in cerebral gray and 
white matter and reduced amygdalae, caudate, hippocampi, and thalami volumes 
(Zeller et al., 2013).  
Notably, chemotherapy is still considered a more positive alternative when 
compared to conventional radiotherapy approaches. Comparable five-year 
progression free survival rates and superior cognitive outcomes have been found 
in children treated for medulloblastoma with surgery and chemotherapy alone 
compared to those treated with radiation therapy (Rutkowski et al., 2005). Similar 
results were found in a sample of children treated for optic pathway gliomas – 
with preserved intellectual functioning in the cohort receiving surgery and 
chemotherapy (M IQ = 107, SD = 17), relative to those receiving a combination of 
surgery, chemotherapy, and radiation (M IQ = 88, SD = 24; Lacaze et al., 2003). 
In summary, use of chemotherapeutic agents in the management of childhood 
brain tumors may limit the extent of neurological and neurocognitive decline in 
survivors, but this conclusion has largely been drawn by comparing non-irradiated 
patients to their irradiated peers. Neurological side-effects of chemotherapeutic 
agents are well established and this treatment modality should not be considered 
benign or ruled-out as a potential source of later neurocognitive deficits. 
Stem Cell/Bone Marrow Transplant/Rescue. In an effort to preclude 
exposure to the neurotoxicity of radiotherapy, young childhood brain tumor 
patients may receive high-dose chemotherapy regimens followed by stem cell 
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(bone marrow) rescue procedures. Because high-dose chemotherapy destroys 
blood-producing marrow, these cells must be supplanted following chemotherapy 
administration. As part of these procedures, the child may either receive bone 
marrow from a matched donor (transplant), or bone marrow stem cells may be 
harvested from the child him/herself if disease has not spread to these cells 
(autologous hematopoietic stem cell rescue; AuHCR). In most instances, these 
procedures have allowed patients to avoid irradiation completely and maintain 5-
year event-free survival rates similar to those achieved by conventional 
radiotherapy plus chemotherapy protocols (57%-83%; Dhall et al., 2008; Gajjar et 
al., 2006). 
Initial studies have demonstrated promise for preserved neurocognitive 
and neurobehavioral functioning in survivors treated with AuHCR protocols. A 
small pilot study assessing neuropsychological functioning in ten children treated 
for malignant brain tumors with an intensive chemotherapy and bone marrow 
rescue protocol found largely intact intellectual, academic achievement, verbal 
and visual memory, and social-emotional skills (Sands, van Gorp, & Finlay, 
1998). Follow-up studies with larger samples (N = 26) report similar findings, 
with verbal and non-verbal intelligence, academic achievement, and social-
emotional and behavioral functioning in the low average to average ranges (Sands 
et al., 2010). Though quality of life outcomes have also been shown to remain 
stable following treatment, younger age at diagnosis and greater time post-
treatment may be associated with attention problems (Sands et al., 2011). 
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Neurological Complications & Comorbidities. Neurological signs and 
symptoms may emerge during the course of treatment and can result from either 
the direct or indirect effects of CNS-based tumors, leading to the initial 
neurological consultation (Ullrich, 2009). The development of neurological 
complications is influenced by patient, treatment, and tumor-related factors 
including age at diagnosis, treatment modality used, and tumor type, size, and 
location. Neoplasms occupying the cranial vault can disrupt neural activity 
directly through local invasion of brain tissue, compression on adjacent structures 
as a result of mass effect, or secondarily through the development of increased 
intracranial pressure (Ullrich, 2009). There is also evidence to suggest that 
neurological morbidity may be influenced by treatment-related factors. For 
example, exposure to cranial radiation may increase risk of developing growth 
hormone deficiency, hypothyroidism (Gurney et al., 2003), or a late-onset seizure 
disorder in survivors of childhood brain tumor (Packer et al., 2003).  
Both in the acute phase and long-term, these tumors can give rise to a host 
of neurological comorbidities including impaired fine and gross motor control, 
hemiplegia, occulomotor abnormalities, impaired vision and hearing, and 
disrupted cranial nerve functioning as well as endocrinopothies (Packer et al., 
2003). Supratentorial tumors occupying eloquent brain tissue often lead to focal 
neurological symptoms reflecting the location and function of specific areas on 
the contralateral side of the body, but brain tumors may also give rise to more 
diffuse neurological signs.  In childhood brain tumor patients, the most common 
presenting neurological symptoms are diffuse in nature and include headache, 
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hydrocephalus, and seizures (Antunes, 2001). The development of hydrocephalus 
and/or seizures will be discussed in greater detail here as they have been shown to 
present a significant risk to neurocognitive outcome. 
Hydrocephalus. Hydrocephalus describes a neurological condition in 
which the normal cycle of cerebral spinal fluid (CSF) flow and/or absorption is 
disrupted. This disruption often results in the excess accumulation of CSF in the 
ventricular system, distending the ventricles and subsequently exerting influence 
on adjacent structures via increased intracranial pressure. Children with 
ependymomas or tumors located in the posterior fossa region are at particular risk 
for developing hydrocephalus as these tumors are positioned in or near the 
cerebral aqueduct which allows CSF to flow between the third and fourth 
ventricle, leading to obstructive hydrocephalus. Typically, surgical resection of 
this space occupying lesion resumes the normal flow of CSF. Non-obstructive 
hydrocephalus may also occur in disseminating tumors (i.e., medulloblastoma) as 
a result of tumor cells blocking reabsorption of CSF at the site of arachnoid villi 
in the meningeal layer (Ullrich, 2009). Increased intracranial pressure may also 
disrupt the cerebral vascular supply and contribute to white matter pathology in 
the periventricular region (Rajagopal et al., 2013). 
Hydrocephalus is typically managed by the placement of a 
ventroperotoneal (VP) shunt, allowing for excess CSF to bypass the obstructive 
lesion. Of note, shunt infections and the need for multiple neurosurgical revisions 
has been found to increase the risk of intellectual decline in other clinical 
populations (Barf et al., 2003). Management may also be achieved surgically 
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through third ventriculostomy, in which an incision is made in the floor of the 
third ventricle restoring circulation of CSF through the ventricular system, which 
has been shown to be effective in children with tumors in the posterior fossa 
region (Sainte-Rose et al., 2001). 
Post-surgical Seizures. New-onset seizures may also emerge following 
tumor resection and contribute to morbidity in survivors. A large retrospective 
study conducted by Packer et al. (2003), evaluating the incidence of neurosensory 
deficits in childhood brain tumor survivors, found that approximately 25% of 
survivors report new-onset seizures following treatment, with increased incidence 
in those receiving radiotherapy and/or chemotherapy. Tumor histology and 
location influence the probability of tumor-associated seizures. Seizures more 
commonly arise from slow-growing/low-grade tumors and those residing in 
supratentorial parenchyma, particularly the frontal and temporal lobes (Rajneesh 
& Binder, 2009). Perioperative anticonvulsant prophylaxis has also been used in 
patients at risk for developing post-operative seizures and is proposed to reduce 
the likelihood of seizure emergence (Zachenhofer, Donat, Oberndorfer, & 
Roessler, 2011). However, results remain inconclusive and this practice has been 
called into question (Sayegh, Fakurnejad, Oh, Bloch, & Parsa, 2014; Sirven, 
Wingerchuk, Drazkowski, Lyons, & Zimmerman, 2004), particularly as anti-
seizure medication has been shown to negatively affect mood and cognition (van 
Breemen, Wilms, & Vecht, 2007). 
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Neuropsychological Late Effects & Morbidity Associated with Treatment 
Modalities 
Brain tumors, and the neurotoxicity of their treatments, negatively impact 
normal brain development and subsequently place survivors at risk for 
neurocognitive deficits that may be chronic in nature (Maddrey et al., 2005). As 
survival rates for pediatric malignancies continue to rise, more attention is now 
being directed towards these neurocognitive “late effects” which appear within 
the first year following treatment and may become more pronounced as survivors 
age and fail to keep pace with peers. In fact, compared with sibling controls, 
survivors of childhood brain tumors are less likely to be employed, have a college 
degree, or marry (Zebrack et al., 2004), not only significantly impacting 
survivors’ quality of life, but also increasing caregiver and family burden 
(Hocking et al., 2011).  
While global intelligence quotients (IQ) have historically been used as the 
metric for measuring these late effects, recent literature has documented the 
deleterious effects of tumors and their treatments on multiple neurocognitive 
domains including attention, academic achievement, memory, executive 
functioning, and social functioning among others (Mulhern & Butler, 2004; 
Robinson et al., 2010; Wolfe et al., 2012). Importantly, the severity of 
neurocognitive late effects is often influenced by the interaction of patient 
demographic factors, tumor- and treatment-related variables, as well as 
neurological comorbidities  (Mulhern, Merchant, Gajjar, Reddick, & Kun, 2004; 
Turner et al., 2009). Identifying neurocognitive domains most susceptible to 
decline following tumor-directed treatments may aid researchers and clinicians in 
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developing and implementing efficacious intervention strategies as survivors 
transition back into daily routines. Below, neuropsychological late effects are 
discussed in relation to treatment-related variables as well as neurological 
comorbidities. 
Surgical Resection. The extent of surgical resection correlates with 
progression free survival, with full resection affording the most favorable 
prognosis (Wisoff et al., 2011). Neurosurgical intervention, however, is not 
without associated neuropsychological risk. In samples of children either treated 
with surgical resection alone, or evaluated prior radiotherapy administration, 
impairments were found in attention, memory, verbal fluency, verbal memory, 
visuospatial organization, and processing speed (Carpentieri et al., 2003; Steinlin 
et al., 2003). However, it is important to note that these children may evidence 
significantly lower performance on multiple neuropsychological domains even 
prior to surgery (Habets et al., 2014), presumably reflecting the impact of the 
tumor itself. Furthermore, the development of perioperative surgical 
complications including shunt infections, stroke, sensory deficits, cranial nerve 
dysfunction, and the need for multiple repeated neurosurgeries, have been shown 
to significantly predict IQ (Kao et al., 1994), visuospatial, and executive deficits 
following treatment (Maddrey et al., 2005). 
Another often understudied complication of surgical resection is cerebellar 
mutism, or posterior fossa syndrome, which occurs in approximately 15% to 25% 
of patients treated for cerebellar tumors (Palmer et al., 2009; Robertson et al., 
2006). This phenomenon is characterized by mutism within the acute 
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postoperative period, with alterations in emotional lability fluctuating between 
inconsolable crying and excessive giggling, typically resolving spontaneously 
within months (Schmahmann, 2004). Compared to those treated for comparable 
tumors who do not develop of cerebellar mutism, these children evidence 
reductions in fronto-cerebellar tractography compared to controls (Soelva et al., 
2013) and worse neurocognitive outcomes (Palmer et al., 2010). In summary, 
neurosurgical management of childhood brain tumors may contribute to 
neuropsychological morbidity, even in the absence of exposure to other empirical 
risk factors. 
Radiation Therapy. Much of the research on neurocognitive late effects 
in pediatric brain tumor survivors has focused on radiotherapy exposure, which is 
proposed to account for the majority of variance in neuropsychological outcomes 
(Reimers et al., 2003; Yeates, Ris, Taylor, & Pennington, 2009). Importantly, 
global intellectual functioning has been used as the standard neurocognitive 
outcome metric in this population. However, more sophisticated modeling of late 
effects has recently yielded a greater understanding of the negative impact 
radiotherapy poses to other neurobehavioral domains. Predictors of cognitive 
outcomes following exposure to radiation therapy are multifactorial and include 
not only treatment-related variables but also may be dependent upon patient 
characteristics. 
Compared to children treated with surgical resection alone, those receiving 
craniospinal radiation evidence significantly lower performance and global IQs 
(Mulhern et al., 1999). The extent of radiotherapy exposure is also not 
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surprisingly a significant predictor of neurocognitive outcome. Retrospective 
studies have documented this dose-dependent relationship, with children 
receiving focal radiation exhibiting higher FSIQ scores (M = 84.5, SD = 14.0) 
than those treated with 25Gy (M = 76.9, SD = 16.6), or 35Gy (M = 63.7, SD = 
15.4; Grill et al., 1999). Evidence from smaller studies also suggest better 
functional status and neurocognitive performance in those treated with focal 
rather than whole-brain or craniospinal radiation (Kleinberg, Wallner, & Malkin, 
1993).  In a Pediatric Oncology Group study for standard-risk medulloblastoma 
patients (R. K. Mulhern et al., 1998), children were randomized to receive either 
standard- (36Gy) or reduced-dose (23.4Gy) cranial radiation. All participants 
underwent neuropsychological assessment between 6 and 10 years post-treatment. 
As hypothesized, FSIQ, reading achievement, and arithmetic achievement scores 
were greater for those in the reduced-dose radiation group. Newly developed 
proton radiotherapy techniques also hold promise for reducing collateral tissue 
damage associated with entry and exit doses of conventional radiotherapy 
techniques, sparing larger volumes of healthy tissue and limiting secondary 
cognitive morbidity (Merchant et al., 2008). 
Research has consistently demonstrated a linear relationship between age 
at radiotherapy exposure and intellectual outcomes, with greater IQ deficits seen 
in children treated with radiotherapy at younger ages (Dennis, Spiegler, 
Hetherington, & Greenberg, 1996; Mulhern et al., 1998; Palmer et al., 2003; Ris, 
Packer, Goldwein, Jones-Wallace, & Boyett, 2001), reflecting the particular 
vulnerability of developing white matter (Mulhern et al., 2001; Mulhern et al., 
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1999; Reddick et al., 2005; Reddick et al., 2003). In fact, regardless of average-
risk (23.4Gy) or high-risk (36-39.6Gy) classification, children under the age of 
seven at diagnosis experience significant annual declines in processing speed 
abilities while their older peers may not (Palmer et al., 2009). Female sex is 
considered an additional independent risk factor as girls evidence greater declines 
in IQ compared to their male counterparts (Palmer et al., 2001). 
These deficits may also be long-lasting and protracted, emerging after the 
first year following treatment and worsening over time as survivors transition into 
adulthood. Palmer et al. (2003) serially tracked 50 survivors of pediatric 
medulloblastoma and found a significant mean loss of 2.21 FSIQ points per year 
following radiotherapy exposure, consistent with other longitudinal research 
documenting an annual mean loss of 2.6 to 4.3 IQ points (Palmer et al., 2001; Ris 
et al., 2001). Importantly, these researchers conclude that survivors do not 
experience a loss of previously acquired skills as they continue to make 
significant improvements in raw score points, though at a rate slower than peers in 
the normative sample. As such, greater time since treatment is also considered a 
risk factor for worse neuropsychological functioning in survivors, particularly 
those surviving beyond ten years (Maddrey et al., 2005). 
Neurocognitive deficits, however, are not limited to global intelligence 
and multiple neuropsychological and neurobehavioral domains may be impacted 
by radiotherapy. Cross-sectional, longitudinal, and meta-analytic studies have 
recognized that survivors may experience deficits in global intellectual 
functioning, attention, working memory, psychomotor speed, processing speed, 
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executive, and academic skills, following CNS-directed irradiation (Mulhern & 
Butler, 2004; Mulhern et al., 2004). Importantly, stimulant medication has been 
shown to be efficacious in the treatment of attention difficulties in childhood brain 
tumor populations (Daly & Brown, 2007). 
Chemotherapy. Because chemotherapeutic regimens are often used in 
conjunction with radiotherapy in childhood brain tumor patients, identifying the 
unique contribution of chemotherapy to neuropsychological outcomes remains 
difficult to address. The issue is further complicated by literature frequently 
studying heterogeneous childhood cancer populations (i.e., ALL, brain tumor, 
neurofibromatosis) that typically undergo dissimilar chemotherapy protocols (i.e., 
duration, frequency, method of administration). Moreover, studies typically draw 
conclusions based on cognitive outcomes relative to radiation-exposed 
comparison groups rather than population-based normative data. As a result, 
findings have been mixed as to whether chemotherapy poses a significant risk to 
neuropsychological functioning. 
Among children treated for medulloblastoma with craniospinal irradiation, 
those receiving concurrent chemotherapy did not differ from unexposed peers in 
terms of intellectual functioning at baseline or several years post-treatment 
(Palmer et al., 2003). This finding is consistent with previous research that failed 
to establish a relationship between chemotherapy and intellectual outcomes, 
which tend to be in the average range (Copeland, Moore, Francis, Jaffe, & 
Culbert, 1996; Lacaze et al., 2003; Ward, Phipps, de Sousa, Butler, & Gumley, 
2009). However, other neurocognitive domains may not be spared following 
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chemotherapy exposure in CNS-tumor populations. For example, in children 
treated for tumors under the age of three with surgery and chemotherapy-only 
protocols, IQ and memory function remained preserved (SS = 98) while executive 
functions did not (SS = 87), and were found to be worse in those treated at 
younger ages (Ward et al., 2009). 
These findings are consistent with meta-analytic studies examining 
cognitive outcomes in pediatric ALL survivors treated solely with intrathecal 
chemotherapy (typically methotrexate). While effect sizes for IQ deficits tend to 
be small (Buizer, de Sonneville, & Veerman, 2009), larger effects are seen for 
domains relating to academic achievement, attention, processing speed, and 
executive functioning (Peterson et al., 2008). So while the effects of 
chemotherapy on cognitive functioning are less severe than those posed by 
conventional radiotherapy techniques, chemotherapeutic agents should not be 
regarded as benign to neuropsychological outcomes. 
Neurological Comorbidities & Risk Factors. Neurological 
comorbidities, emerging directly as a result of space-occupying intracranial 
lesions or secondarily through treatment exposures, contribute significantly to 
neuropsychological morbidity in survivors of childhood brain tumor. It is 
important to note that there is an inextricable relationship between patient-, 
tumor-, and treatment-related factors in the development of these neurological 
conditions, which may interact to influence cognitive morbidity in survivors. For 
example, prognosis is dependent upon the extent of surgical resection, which is 
largely determined by tumor location (Pollack, 2011), and tumor location may 
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also predict the development of secondary hydrocephalus (Ullrich, 2009) and 
post-surgical seizures (Rajneesh & Binder, 2009). Furthermore, late-occurring 
stroke risk increases with radiation exposure in a dose-dependent fashion (Bowers 
et al., 2006), and radiation targets in the sellar region involving the HPA axis 
contribute to endocrine dysfunction (Sklar & Constine, 1995). Additionally, 
younger patients are at the greatest risk for radiation-induced white matter loss 
(Reddick et al., 2005) and children who undergo multiple neurosurgical 
interventions exhibit lower performance IQs and greater executive dysfunction 
compared to those treated with a single resection (Ward et al., 2009). So although 
the emergence of neurological sequelae is often associated with more extensive 
disease pathology and treatment, the presence of these comorbidities remains an 
additional independent risk factor for later neurocognitive difficulties.  
Large multi-institution studies (N > 1,600) comparing long-term survivors 
of childhood brain tumors to sibling controls reveal survivors are at elevated risk 
for hearing impairments (RR = 17.3), legal blindness (RR = 14.8), motor 
difficulties (RR = 2.0), seizures (RR = 12.6;(Packer et al., 2003), and stroke (RR 
= 29.0; Bowers et al., 2006). Neurosensory deficits may result from the direct 
influence of the lesion (i.e., optic pathway glioma, acoustic schwannoma) or 
associated treatments (i.e., platinum-based chemotherapy, surgical resection; 
Turner et al., 2009). It is important to note that even mild neurosensory 
weaknesses may impede accurate assessment of neuropsychological abilities, 
making it difficult to determine the relationship between these variables. More 
research has been focused on neurological comorbidities. 
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Merchant et al. (2004) performed a serial evaluation of 50 children with 
hydrocephalus associated with ependymal tumors, both before and after focal 
radiotherapy. In regression analyses, patients with greater ventricular dilation at 
presentation performed more poorly on standardized intelligence tests following 
surgery, and were more likely to exhibit an increase on testing following 
radiotherapy, likely reflecting the significant influence of hydrocephalus in the 
acute stage. Furthermore, children requiring the placement of a VP shunt perform 
worse on measures of intelligence, reading and arithmetic achievement, as well as 
parent- and teacher-rated school performance compared to those with tumor-
associated hydrocephalus not requiring shunt placement (Mabbott et al., 2005; 
Merchant et al., 2004; Reimers et al., 2003). The development of hydrocephalus 
may also impinge on other cognitive domains including attention-span and 
processing speed, both acutely and long-term, even in cases not severe enough to 
warrant placement of a VP shunt (Stargatt, Rosenfeld, Maixner, & Ashley, 2007).  
Taken together, hydrocephalus should be regarded as an empirically-based risk 
factor for reduced cognitive functioning in brain tumor survivors. 
Post-operative seizures have been associated with a reduction in survivors’ 
overall quality of life (Baker, Jacoby, Buck, Stalgis, & Monnet, 1997; Englot, 
Berger, Barbaro, & Chang, 2012), as well as their information processing speed, 
executive functioning, attentional control, and psychomotor speed (Klein et al., 
2003). Prophylactic treatment approaches have been called into question (Sayegh 
et al., 2014), particularly as anticonvulsant medications themselves pose a 
substantial risk to cognition (van Breemen et al., 2007). Taken together, sensory 
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and neurological conditions significantly contribute to neurocognitive difficulties 
which may render survivors unable to live independently (Ness et al., 2010) and 
place significant demands on caregivers and families (Deatrick, Mullaney, & 
Mooney-Doyle, 2009; Hocking et al., 2011). 
 
Quantification of Risk: Treatment Intensity & Neurological Risk 
Despite extensive literature establishing the association between tumor- 
and treatment-related risks and neurocognitive outcomes, most studies have used 
univariate analyses to explore the relationship between a single risk factor and 
later cognitive morbidity, with few examining their potential interactive influence 
(Reimers et al., 2003). An understanding of the unique role that individual risk 
factors play in determining survivor outcomes has been critically important for 
guiding tumor management techniques, and their measurement has become 
increasingly sophisticated. For example, Ris et al. (2005) used information from 
3D conformal therapy and radiation dosimetry to generate precise radiobiological 
models quantifying tissue damage, which have been shown to predict cognitive 
outcomes. However this type of complex model cannot feasibly be generated in 
daily practice, limiting clinical utility. Moreover, treatment approaches for 
childhood brain tumors are almost always multimodal and secondary medical, 
endocrine, and neurological comorbidities are the rule rather than the exception 
(Bowers et al., 2006; Geenen et al., 2007; Gurney et al., 2003; Packer et al., 
2003).  
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Clinically useful measures designed to quantify risk exposure in the 
childhood brain tumor population, considering both treatment intensity and 
secondary neurological complications, are lacking. Ater et al. (1996) developed 
the Neurological Severity Score, designed to measure the cumulative influence of 
adverse medical and neurological events associated with tumor treatments. While 
this scale was found to be moderately correlated with later survivor cognitive 
functioning (i.e., performance IQ, attention, memory, visuospatial skills; ps = -.29 
to -.38), its calculation required a review of medical records across multiple time-
points and proved to be time prohibitive for regular clinical use. 
Based on the work of Ater and colleagues (1996), the Neurological 
Predictor Scale (NPS; Micklewright et al., 2008) was designed to reduce the effort 
needed to quantify these tumor-related risk factors (Appendix A). Importantly, 
this clinician-generated checklist quantifies empirically derived 
neuropsychological risk factors for both treatment and neurological comorbidities. 
Preliminary investigation supported the scale’s utility in predicting global 
intellectual outcomes in childhood brain tumor survivors (Micklewright et al., 
2008), with later studies providing conflicting evidence in predicting survivor 
adaptive functioning with the NPS (McCurdy, Rane, Daly, & Jacobson, 2016; 
Papazoglou et al., 2009). 
The Pediatric Neuro-Oncology Rating of Treatment Intensity (PNORTI; 
Appendix B) was developed as an extension of the Intensity of Treatment Rating 
Scale (Kazak et al., 2012; Werba et al., 2007), a psychometrically-valid tool 
designed to quantify the intensity of childhood cancer treatments. The PNORTI 
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was further refined for use with pediatric brain tumor populations more 
specifically (Deatrick et al., 2013), and classifies treatment variables across 
varying degrees of radiation and chemotherapy exposure, ranging from low to 
high intensity. The predictive validity and clinical utility of the PNORTI have yet 
to be established. 
Relative to the PNORTI, the NPS lacks specificity for quantifying 
treatment exposures. The PNORTI classifies treatment intensity across treatment 
exposures and allows the clinician to specify varying degrees of chemotherapy 
intensity. The NPS on the other hand dichotomizes chemotherapy exposure (i.e., 
administered vs. not administered) and fails to include stem cell rescue 
procedures, though does allow for the characterization of highly comorbid 
neurological conditions.  
Many specialized care-providers are involved in the treatment, diagnosis, 
management, assessment, and rehabilitation of childhood brain tumor patients 
(e.g., neuro-oncologists, neurologists, nurse practitioners, 
neuropsychologists/psychologists, occupational/physical therapists etc.). Both the 
NPS and PNORTI have the potential to provide these caregivers with a single, 
easy to communicate rating of treatment intensity and neurological risk. Much 
like the Glasgow Coma Scale (GSC) affords medical professionals the ability to 
readily communicate a single rating of injury severity in traumatic brain injured 
patients, the NPS and PNORTI may be able to quantify tumor- and treatment-
related risk in childhood brain tumor populations. Furthermore, and a large part of 
the popularity and clinical utility of the GCS, these rating scales can be easily 
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generated with very little clinical training, and do not require cost-prohibitive 
techniques and equipment. Given a single quantified rating of neurological risk in 
childhood brain tumor populations, nurse practitioners and others working closely 
with affected families will be better situated to address family and patient 
concerns and arrange for future rehabilitation and accommodation services. 
Current Study 
Rationale 
Given the lack of empirically-validated late-effect risk quantification 
scales for the pediatric brain tumor survivor population, the current study aims to 
add to this literature by exploring the predictive qualities of two clinician-
generated measures (NPS and PNORTI). Evidence suggests that 
neuropsychological late effects begin to emerge on standardized testing 
approximately one year following the conclusion of tumor-directed therapies and 
may not reach clinically significant levels until three to four years post-treatment 
(Duffner, Cohen, & Parker, 1988; Spiegler, Bouffet, Greenberg, Rutka, & 
Mabbott, 2004). The present study proposes to measure neurocognitive 
functioning approximately nine months post-treatment conclusion. Although this 
timeframe may be premature for detecting cognitive and adaptive morbidity in 
this population, there is a relative paucity of literature examining the subacute and 
early-stage survival period in relation to neurocognitive status (Gragert & Ris, 
2011). Furthermore, should treatment-related variables captured by the NPS and 
PNORTI provide significant predictive value for neuropsychological performance 
within this early-survivorship period, providers may be better positioned to 
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mitigate latent cognitive and functional difficulties associated with long-term 
survivorship by implementing empirically-based intervention strategies. 
Aims 
The present study seeks to examine the utility of treatment-related 
neurological comorbidities and the intensity of tumor-directed therapies in 
predicting cognitive and adaptive outcomes in adolescent survivors of childhood 
brain tumor nine months after the conclusion of treatment. More specifically, this 
study aims to establish the predictive validity of two quantification scales 
designed to measure the cumulative risk posed by these treatments within a 
sample followed prospectively at the conclusion of tumor-directed therapies. A 
greater understanding of predictors of neurocognitive outcomes in adolescent 
brain tumor survivors may contribute to better therapeutic planning as this 
population transitions into young adulthood. 
Hypotheses 
In a sample of survivors of pediatric brain tumors it was hypothesized that: 
1) higher scores on the Neurological Predictor Scale (NPS) would predict worse 
neurocognitive performance (processing speed, auditory attention, working 
memory, executive functioning, verbal memory, and adaptive skills) nine months 
following the cessation of tumor-directed treatment when controlling for Baseline 
performance on these measures; 2) the Pediatric Neuro-Oncology Rating of 
Treatment Intensity (PNORTI) would significantly predict neuropsychological 
functioning nine months after exposure to tumor-directed treatments when 
controlling for Baseline functioning in this population; and, 3) neurological 
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comorbidities included on the NPS, when incorporated with treatment intensity 
variables captured by the PNORTI, would provide incremental validity for 
predicting neuropsychological outcomes across these domains. 
 
Methods 
The present study was conducted as part of an IRB-approved protocol 
supported by the Division of Oncology at the Children’s Hospital of Philadelphia 
(CHOP). This protocol was designed to prospectively examine the relationship 
between neurocognitive functioning and family functioning in survivors of 
childhood brain tumor. For the purposes of the current study, the procedures 
outlined in this parent-protocol were employed; however, only demographic, 
cognitive, and treatment-related factors were examined as family systems factors 
are not a focus of this study.  
Procedures 
After IRB approval, parents of children being treated for a brain tumor 
were identified by the Neuro-Oncology team at CHOP as being eligible for 
participation in the study. Those identified as meeting the eligibility criteria were 
mailed a recruitment letter describing the study protocol. Families interested in 
participating were provided more information either via phone or in-person during 
regularly scheduled clinic appointments. Informed consent was obtained from all 
enrolled individuals prior to their participation in the study. 
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Consenting participants (both children and caregivers) were administered 
study measures at two time-points following the conclusion of tumor-directed 
treatments: ‘Baseline’ data were collected within the first 4-5 months after the end 
of tumor-directed medical treatments, and measures were again administered at a 
‘Follow-up’ appointment 6 (± 2) months following Baseline. At each time point, 
survivors were be administered a brief neuropsychological battery measuring 
graphomotor processing speed (WISC-IV Processing Speed Index), auditory 
attention (WISC-IV Digit Span Forward) and working memory (WISC-IV Digit 
Span Backward), executive functioning (TEA-Ch Creature Counting), and 
auditory verbal memory (WRAML-2 Story Memory). Caregivers also completed 
measures of daily executive behavior (BRIEF) and adaptive skills (BASC-2). A 
brief screening of general intellectual functioning (WASI-II) was also 
administered at Baseline. Data collection at each time point took approximately 
1.5 hours and coincided with the child’s regularly scheduled Follow-up medical 
appointments. For participants unable to travel to the hospital, study procedures 
were conducted in the participant’s home. For eligible participants who completed 
routine clinical assessments within the Department of Neuropsychology in 
relation to their transition off tumor-directed treatments, scores were obtained 
from medical records and used in subsequent analyses. At each time point, 
participants will receive a $25 gift card in appreciation of their time and 
participation.  
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Recruitment and Eligibility 
Eligible participants included youth who underwent, and are transitioning 
off, any combination of tumor-directed treatments for the management of their 
brain tumor at the Children’s Hospital of Philadelphia. Inclusion criteria include 
survivors who: 1) are between the ages of 6 and 16 years at the time of 
enrollment; 2) recently concluded tumor-directed treatment for the management 
of a brain tumor; and, 3) were treated with any combination of surgical resection, 
chemotherapy, or focal, cranial, or craniospinal radiation (including proton beam 
radiotherapy). This age range was chosen due to the lack of psychometrically 
sound measures designed to assess neurocognitive functioning prior to the age of 
5 and beyond 16 years, and ensure measurement consistency across ages. 
Participants were excluded if the child/adolescent: 1) had been diagnosed with a 
multi-system genetic disorder that may influence neurocognitive functioning; 2) 
evidenced neurodevelopmental delays prior to the identification and diagnosis of 
their brain tumor; 3) only underwent tumor biopsy (and received no additional 
tumor-directed therapies) for the management of their brain tumor; and, 4) are 
were unable to read and understand written English. 
Measures 
Neurological Predictor Scale (NPS; Micklewright et al., 2008). The 
Neurological Predictor Scale (NPS) is a clinician-generated checklist designed to 
quantify the severity and extent of neurological and medical complications 
associated with a child’s brain tumor and/or related treatment (Appendix A). 
Items on the NPS were selected based upon existing research (Ater et al., 1996; 
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Ris & Noll, 1994), and include relevant treatment factors and neurological 
complications: extent of neurosurgical intervention, radiotherapy, chemotherapy, 
and other comorbid neurological concerns. Rated on an ordinal scale, higher 
values reflect more extensive tumor-related burden and overall trauma to neural 
tissue (Micklewright et al., 2008; Ris et al., 2005). Treatment and neurological 
variables were extracted from the patient’s medical record by a trained graduate 
research assistant and verified for accuracy by neuro-oncology nurse practitioners 
(CD and RP). Final NPS scores, based on extracted medical data, were generated 
by a trained neuro-oncologist (MF) and a neuro-oncology nurse practitioner 
(WH). 
Pediatric Neuro-Oncology Rating of Treatment Intensity (PNORTI). 
The Pediatric Neuro-Oncology Rating of Treatment Intensity (PNORTI) was 
developed from a well-validated, retrospectively generated rating scale classifying 
the intensity of pediatric cancer treatments (Werba et al., 2007). This scale is 
modeled after the Intensity of Treatment Rating Scale (ITR;(Kazak et al., 2012; 
Werba et al., 2007), a measure designed to classify the intensity of pediatric 
cancer treatments as a whole, by ranking diseases and their associated treatments 
into three intensity levels ranging from minimally intensive to most intensive. The 
PNORTI seeks to quantify the intensity of treatments for pediatric brain tumors 
specifically, including Level 1, Level 2 and Level 3, with higher scores indicating 
more intensive treatment exposure (Appendix B). Treatment variables were 
abstracted from the participant’s medical records in the same manner noted above, 
verified by neuro-oncology nurse practitioners (CD and RP), and PNORTI scores 
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were generated by a neuro-oncologist (MF) and neuro-oncology nurse practitioner 
(WH). 
Wechsler Abbreviated Scale of Intelligence – Second Edition (WASI-
II; Wechsler, 2011). The Wechsler Abbreviated Scale of Intelligence – Second 
Edition (WASI-II) is an individually administered test designed to provide a brief 
estimate of intelligence for individuals aged 6 to 89 years. Given its abbreviated 
design, the WASI-II is not designed for comprehensive examination of 
intelligence, but is ideally suited for the purposes of estimating IQ for research 
projects (Strauss, Sherman, & Spreen, 2006). The test consists of four measures of 
both verbal and non-verbal abilities. For this study, only one verbal (Vocabulary) 
and one non-verbal (Matrix Reasoning) subtest will be administered which still 
allows for the generation of a full scale IQ (FSIQ) score (Wechsler, 2011). These 
two subtests should take approximately 15 minutes to administer. The Vocabulary 
subtest requires participants to define a series of words read aloud by the 
examiner and is considered a measure of crystallized knowledge, language 
development, and verbal comprehension (Sattler & Dumont, 2004). For the 
Matrix Reasoning subtest, participants are presented patterned matrices of which 
a piece is missing, requiring them to select from an array of possible patterns that 
best completes the larger configuration. Matrix Reasoning measures nonverbal 
intelligence broadly, and requires intact visual processing and visual-perceptual 
organization skills (Sattler & Dumont, 2004). 
The WASI-II was normed on 1,100 children and adolescents between the 
ages of 6 and 16 years, sampled from geographically and demographically 
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representative U.S. populations. Internal consistency estimates for the Vocabulary 
and Matrix Reasoning subtests, averaging across ages 6 to 16 years, are high (α = 
.91 and .87, respectively). Test-retest reliability coefficients are also adequate 
within this age range (Vocabulary: r = .90; Matrix Reasoning: r = .79). The 
WASI-II is highly correlated with another existing measure of intelligence in 
children (WISC-IV), with coefficients between analogous subtests of r = .78 
(Vocabulary) and r = .73 (Matrix Reasoning). 
Wechsler Intelligence Scale for Children – Fourth Edition (WISC-IV; 
Wechsler, 2003). The Wechsler Intelligence Scale for Children – Fourth Edition 
(WISC-IV) is a widely used individually administered measure of intelligence for 
children and adolescents aged 6 to 16 years. For this study, only subscales 
designed to measure processing speed (Symbol Search and Coding), attention, 
and working memory (Digit Span) will be administered. The Digit Span subtest 
consists of Forward and Backward conditions. In the Forward condition, 
participants are asked to repeat numbers verbatim as read aloud by the examiner. 
The Backward trials require the child to repeat numbers read aloud by the 
examiner, but in reverse order (Flanagan & Kaufman, 2004). Digit Span is 
sensitive to various cognitive factors, but largely, the Forward trial is considered a 
test of focused attention and auditory short-term memory, while the Backward 
condition measures auditory working memory (Sattler & Dumont, 2004). The 
Symbol Search and Coding subtests are core processing speed measures of the 
WISC-IV. In Symbol Search, the child must scan a group of symbols and specify 
the presence or absence of a target symbol within a specified time limit. Coding 
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requires the child to copy symbols that are paired with keyed shapes or numbers 
as quickly and accurately as possible (Strauss et al., 2006). These subtests are 
measures of speeded visual-perceptual scanning and discrimination, as well as 
psychomotor speed (Sattler & Dumont, 2004). 
The standardization sample for the WISC-IV consisted of 2,200 children 
between the ages of 6 and 16 years. Test-retest reliability coefficients for Symbol 
Search and Coding are good (rs = .79 and .85, respectively). Internal consistency 
estimates for the Digit Span subtest across all age-ranges were also strong (α = 
.87). Symbol Search, Coding, and Digit span also evidence good correlation 
coefficients when compared against the WISC-III (rs > .67). 
Test of Everyday Attention for Children (TEA-Ch; Manly, Robertson, 
Anderson, & Nimmo-Smith, 1999). The Test of Everyday Attention for 
Children (TEA-Ch) is a performance-based measure of attentional and executive 
processes for children and adolescents. The full version comprises a battery of 
nine subtests that measure focused, sustained, and controlled attention – though 
only the Creature Counting subtest is used in the present study. Creature Counting 
requires the child to shift attentional focus and suppress an ongoing response 
while switching between counting up or down in response to a visually presented 
cue (arrow; Strauss et al., 2006). This subtest is often considered a measure of 
attentional switching and attentional control, but may also be regarded as a test of 
executive functioning given the total time score’s correlation with other speeded 
measures of executive processing (Trails-B, r = .21; Manly, Anderson, Nimmo-
Smith, Turner, & Robertson, 2001). 
McCurdy, 36 
 
The standardization sample for the TEA-Ch was comprised of 293 
Australian children between 6 and 16 years of age. According to the manual, test-
retest reliability for Creature Counting accuracy scores were r = .71, and lower for 
the timing score (r = .57). TEA-Ch Creature Counting timing demonstrates non-
significant correlations with Trails A performance (r = .19), which places less 
demand on attentional switching, but significant correlations with Trails B (r = 
.21), lending support to the subtest’s construct validity. 
Wide Range Assessment of Memory and Learning – Second Edition 
(WRAML-2; Sheslow & Adams, 2003). The Wide Range Assessment of 
Memory and Learning – Second edition (WRAML-2) is a battery designed to 
measure memory skills in children and adults ages 5 to 90 years. The Story 
Memory subtest is a measure of auditory verbal memory in which the participant 
must recall as much information as possible from two short stories presented 
orally by the examiner. Memory is assessed by both immediate and delayed 
(approximately 15 minutes) free-recall trials, as well as multiple choice 
recognition trials for each story. The Story Memory subtest yields scaled scores 
for immediate free-recall, delayed free recall (SM-DFR), and a delayed 
recognition performance. A Story Memory Retention score can also be generated 
by comparing the immediate and delayed free recall trials. Normative data were 
provided by 1,200 individuals aged 5 to 90 years. The Story Memory subtest 
evidences high internal consistency coefficients within children aged 5 to 17 years 
(α = .88-.95) and good test-retest reliability (r = .75). 
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Behavior Rating Inventory of Executive Function (BRIEF; Gioia, 
Isquith, Guy, & Kenworthy, 2000). The Behavioral Rating Inventory of 
Executive Function (BRIEF) is an 86-item caregiver-report scale designed to 
measure daily executive function behaviors in children and adolescents 5-18 years 
old. Executive behaviors encompass skills for regulating cognitive, behavioral, 
and emotional functioning in order to engage in effective problem-solving 
behavior. As opposed to performance based measures of executive functioning 
that are administered in a structured testing environment, the BRIEF offers a more 
ecologically grounded report of a child’s executive functioning by relying on 
caregiver report of daily executive behaviors (Gioia et al., 2000). Caregivers are 
asked to rate their child’s behavior on a three-point scale (“Never”, “Sometimes”, 
and “Often”) as they occur over the past six months. Eight individual scales are 
derived, subsumed under two broader factors and an overall composite score. 
Subscales reflect the child’s ability to shift cognitive set and think flexibly (Shift), 
resist automatic behaviors/impulses (Inhibit), modulate emotions (Emotional 
Control), initiate tasks and generate problem-solving strategies (Initiate), sustain 
and manipulate information in mind for performing multi-step tasks (Working 
Memory), anticipate future events and plan and sustain a problem-solving 
approach towards a goal (Plan/Organize), organize personal belongings 
(Organization of Materials), and self-monitor goal-directed actions (Monitor). 
These first three subscales contribute to the Behavioral Regulation Index (BRI), 
while the remaining load on the Metacognition Index (MI). These two factors 
together constitute the Global Executive Composite (GEC) which evidences high 
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internal consistency (α = .98) and good test-retest reliability (r = .81) in clinical 
samples (Gioia et al., 2000). The GEC also demonstrates good concurrent 
validity, with the Working Memory subscale correlating highly with the Attention 
Problems subscale of the Behavior Assessment System for Children (r = .69), and 
the Inhibit subscale correlating with the ADHD-Rating-Scale-IV’s 
Hyperactivity/Impulsivity scale (r = .73). The GEC also demonstrates non-
significant convergence with Obsessive-Compulsive and Antisocial subscales of 
the Conners’ Rating Scale (rs < .13), suggesting divergent, and ultimately, strong 
construct validity. 
Behavior Assessment System for Children – Second Edition (BASC-2; 
Reynolds & Kamphaus, 2006). The Behavior Assessment System for Children – 
Second Edition is a broad-band caregiver rating scale designed to measure 
multiple aspects of child behavior and personality. Both Child (ages 6-11 years) 
and Adolescent (ages 12-21) versions of the form yield an overall Adaptive Skills 
Composite (ASC), with higher scores reflective of greater functional skills. The 
ASC is comprised of five scales: Adaptability, Social Skills, Leadership, 
Activities of Daily Living, and Functional Communication. The ASC 
demonstrates strong internal consistency (α = .94-.95) and stability over time 
(test-retest reliability; r = .84-.93) across Child and Adolescent forms. 
Data Analysis Plan 
Descriptives & Interrater Reliability. Appropriate descriptive statistics 
(e.g., frequencies, means, standard deviations, ranges) were generated for all 
demographic and study variables. Exploratory visuals (e.g., histograms, 
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scatterplots, boxplots) were used to assess for assumptions of normality, in 
addition to quantitative methods for assessing skew, kurtosis, and outliers. Paired-
samples t-tests and Cohen’s d effect sizes were used to examine differences 
between Baseline and Follow-up performance across neuropsychological 
variables. Intraclass correlation coefficients (ICC) were generated to determine 
the interrater reliability of NPS total scores, and Cohen’s κ was used to examine 
consistency between PNORTI ratings. A consensus between raters was reached to 
resolve any discrepancies in NPS and PNORTI ratings, and the agreed upon 
values were used in subsequent analyses. Given the relatively small sample size, 
statistical corrections (e.g., Bonferroni) were not applied. For all analyses, an a 
priori alpha level of .05 was used and appropriate effect sizes were examined. 
Predictive Utility. To evaluate the predictive utility of the NPS 
(Hypothesis 1) and PNORTI (Hypothesis 2) hierarchical multiple linear 
regressions were employed. Follow-up neuropsychological performance was 
entered as the dependent variable in all regressions with the Baseline scores of the 
dependent variable of interest in the first step of the model in order to control for 
Baseline functioning (Model 1), and NPS or PNORTI scores were entered into the 
second step to examine the contribution of these scales in predicting Follow-up 
performance (Model 2). For example, with Follow-up WISC-IV PSI scores 
entered as the dependent variable, Baseline WISC-IV PSI scores were entered 
into the first block, and the NPS was entered into the second block. This method 
was repeated for each construct of interest. To assess statistical and clinical 
significance, R2Δ values and effect sizes (f2) were generated with values of 0.02, 
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0.15, and 0.35 representing small, medium, and large effects, respectively (Cohen, 
1988).  
Incremental Validity of Neurological Comorbidities. In order to 
examine the incremental validity of empirically-derived neurological risk factors 
above-and-beyond treatment intensity (Hypothesis 3), hierarchical multiple linear 
regressions were used as per Haynes and Lench (2003). Baseline performance on 
the dependent variable of interest was entered into the first block (Model 1), 
followed by total PNORTI scores (treatment intensity) in the second block 
(Model 2), and a sum of neurological risk factors and comorbidities (multiple 
neurosurgeries, hydrocephalus, seizure prophylaxis, hormone dysfunction, stroke) 
in the final block (Model 3). Neurocognitive domains of interest noted above 
were entered separately as dependent variables in each regression. As before, R2Δ 
and effect size change (f2Δ) were used to assess the added contribution of 
neurological risk factors. Effect size change (f2Δ) values were calculated by 
subtracting the variance accounted for by neurological risk factors (R2A) from the 
combined variance accounted for by neurological risk factors, PNORTI scores, 
and Baseline functioning (R2AB), divided by the unexplained variance (Soper, 
2016). 
Power Analysis. A-priori power analyses suggested that to produce a 
power of 0.80, with an alpha level of 0.05 and with three predictors in the model 
(Baseline Performance, PNORTI, Neurological Risk), 56 participants would be 
required to detect a medium effect (.15) in a hierarchical multiple linear 
regression equation. 
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Results 
Participants & Descriptives 
Figure 1 displays recruitment, enrollment, and retention information for 
the present sample. A total of 50 participants were enrolled and completed 
Baseline assessments. Fifteen participants were lost to Follow-up for various 
reasons that included passive refusal (n = 5), tumor recurrence (n = 5), family 
withdrawal (n = 2), death (n = 2), or relocation (n = 1; Figure 1). Those lost to 
Follow-up did not differ from those who remained enrolled in terms of sex, χ2 (1, 
N = 50) = 0.31, p = .58, or ethnicity, χ2 (3, N = 50) = 6.96, p = .07. Independent 
samples t-test revealed that those lost to Follow-up had significantly higher 
PNORTI sores (M = 1.60, SD = 0.74) compared to those who remained enrolled 
(M = 1.17; SD = 0.38) t(17.32) = 2.13, p = .05. Groups did not differ with respect 
to NPS scores, t(48) = 1.47, p = .15, time since diagnosis t(48) = -0.75, p = .46, or 
time since completion of treatment, t(48) = -0.11, p = .92. 
The final sample consisted of 35 survivors (51.40% female) ranging in 
ages from 6 to 15 years (M = 11.00, SD = 2.71). Post-hoc power analysis revealed 
a 58.81% power to detect a medium effect (.15) with alpha of .05 and three 
predictors in the model with a sample size of 35, indicating that the present study 
was underpowered. The sample consisted primarily of Caucasian (85.70%) and 
African American (11.40%) youth. Additional participant demographic 
information is displayed in Table 1. The majority of participants were diagnosed 
with low grade astrocytoma (28.60%), low grade glioma (22.90%), Ependymoma 
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(11.40%), or ganglioglioma (11.40%). Neurological comorbidities were 
experienced by most survivors (77.14%). Sixty percent of the participants had at 
least one neurological comorbidity, with 11.40% and 5.70% experiencing two or 
three comorbidities, respectively. Diagnoses and treatment histories are outlined 
in Table 2. Age at diagnosis was not correlated with any dependent variables of 
interest (rs = -0.07 – -0.31, ps > .05), and was therefore not included as a 
covariate in subsequent analyses. 
Neuropsychological Functioning 
Baseline and Follow-up neuropsychological test performance is presented 
in Table 3. Baseline global intellectual functioning (WASI-II) was estimated to be 
in the Average range (M = 98.39, SD = 17.04), though ranged from standard 
scores of 67 to 130. Paired-samples t-tests revealed no significant differences 
between Baseline and Follow-up performances across dependent variables of 
interest (ds = 0.01 – 0.10), and all scores remained in the Average range 
compared to normative samples. 
Interrater Reliability: NPS & PNORTI 
Interrater reliabilities for NPS and PNORTI scores between the neuro-
oncologist (MF) and nurse practitioner (WH) were examined. NPS total scores 
between the raters was excellent, ICC = 0.97 (95% CI = 0.94 -0.98), and 
agreement between raters on the PNORTI were also high, κ = .82, p < .01. NPS 
total scores ranged from 1 to 9 (M = 4.69, SD = 2.07). PNORTI scores ranged 
from “Level 1” (n = 29; 82.90%), to “Level 2” (n = 6; 17.10%), with no 
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participants rated as having “Level 3” intensity treatment. NPS and PNORTI 
scores were moderately correlated, (rpb = 0.74, p < .01).  
Hypothesis 1 & 2: Predictive Utility 
Assumptions of hierarchical multiple linear regressions were checked for 
all NPS and PNORTI analyses. For all regressions, there was linearity as assessed 
by partial regression plots and a plot of studentized residuals against predicted 
values. Durbin-Watson statistics revealed independence of residuals. 
Homoscedasticity was assessed by visual inspection of the plot of studentized 
residuals against unstandardized predicted values, and confirmed by Breusch-
Pagan tests (Cook & Weisberg, 1983). There was no evidence of multicollinearity 
as determined by VIF and tolerance values. All dependent variables were largely 
normally distributed as assessed by visual examination of histograms and 
Shapiro-Wilk tests. No variables were significantly skewed or kurtotic. All 
studentized deleted residuals, leverage values, and Cook’s distance values were 
within acceptable limits as were Q-Q Plots. 
Neurological Predictor Scale (NPS). Results of hierarchical multiple 
regressions examining the predictive utility of the NPS are presented in Table 4. 
Baseline functioning predicted a significant amount of variance in Follow-up 
performance for all measures (R2 = 0.23 – 0.62; f2 = 0.30 – 1.63). NPS scores did 
not explain a significant amount of additional variance in neuropsychological 
functioning after controlling for baseline performance on PSI (R2Δ = 0.02), DSF 
(R2Δ = 0.01), DSB (R2Δ = <0.01), Creature Counting Accuracy (R2Δ = 0.01), 
SM- DFR (R2Δ = <0.01), BRIEF GEC (R2Δ = 0.03), or Adaptive Skills (R2Δ = 
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0.03; all ps > .05). Effect sizes for the additional explained variance were small 
(f2Δ = 0.00 – 0.05). 
Pediatric Neuro-Oncology Rating of Treatment Intensity (PNORTI). 
Hierarchical multiple regression results for the predictive utility of the PNORTI 
are presented in Table 5. Examination of Model 2 shows that the PNORTI did not 
predict a significant amount of variance in Follow-up performance on PSI (R2Δ = 
0.01), DSF (R2Δ = 0.02), DSB (R2Δ = 0.01), Creature Counting Accuracy (R2Δ = 
<0.01), SM-DFR (R2Δ = <0.01), BRIEF GEC (R2Δ = 0.02), or Adaptive Skills 
(R2Δ = <0.01) after controlling for Baseline functioning on these measures (all ps 
> .05). Changes in effect size were small (f2Δ = 0.00 – 0.05). Baseline and 
Follow-up performances for those with Level 1 (n = 29) and Level 2 (n = 6) 
treatment intensity histories are displayed in Figure 2. Paired samples t-tests 
revealed no significant difference between Baseline and Follow-up performances 
when Level 1 and Level 2 intensity groups were examined independently (ps > 
.05). Effect sizes (presented as Cohen’s d) for those in the Level 1 Intensity group 
were very small for all measures, ranging from d < 0.01 to 0.12, while those for 
the Level 2 Intensity group ranged from small (CC Acc < 0.01; ASC = 0.04; PSI 
= 0.25; DSF = 0.24; SM-DFR = -0.22) to medium (DSB = 0.55). Paired-samples 
correlations between Baseline and Follow-up performances in the Level 1 
Intensity group were significant across all measures (rs = 0.49 – 0.79, ps ≤ .01). 
Baseline and Follow-up performances for the Level 2 Intensity group were not 
correlated (rs = 0.29 – 0.78, ps = .07 – .58) save for SM-DFR (r = 0.84, p = .04). 
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Hypothesis 3: Incremental Validity of Neurological Comorbidities 
Neurological risk factors and comorbidities included a history of 1) 
multiple surgical resections, 2) endocrine dysfunction, 3) seizure prophylaxis, 4) 
hydrocephalus, and 5) stroke. Given sample size limitations, a conglomerate 
variable of neurological risk factors was created based on the presence or absence 
of these comorbidities, ranging from 0 (no neurological risk factors) to 5 (all 
neurological risk factors). Scores ranged from 0 to 3 (M = 1.20, SD = 0.80), with 
6 (17.10%) experiencing no neurological risks, 18 (51.40%) with one risk factor, 
9 (25.70%) with two, and 2 (5.70%) with three risk factors.  
Hierarchical multiple regressions were used to evaluate the incremental 
validity of neurological risk factors and comorbidities in predicting Follow-up 
performance above-and-beyond Baseline performance and treatment intensity 
(PNORTI), (Table 5; Model 3). The inclusion of neurological risk factors and 
comorbidities did not explain a significant amount of additional variance above-
and-beyond Baseline performance and PNORTI scores on any outcome variables 
of interest (R2Δ = <0.01 – 0.05, ps > .05). In Pearson correlations, neurological 
comorbidities and risks were associated with survivor Baseline DSF (r = -0.41, p 
= .02) and SM-DFR (r = -0.44, p = .01), as well as Follow-Up DSF (r = -0.44, p = 
.01). 
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Discussion 
The present study is the first to prospectively examine the utility of the 
NPS and PNORTI for predicting subacute neuropsychological functioning in a 
sample of childhood brain tumor survivors. Both the NPS and PNORTI were 
readily generated by practitioners via medical record review with strong interrater 
reliability. Contrary to the first hypothesis, results revealed no significant 
association between NPS or PNORTI scores and neuropsychological functioning 
in youth approximately nine months following the conclusion of brain tumor 
treatment. In addition, results did not support the second hypothesis as tumor and 
treatment-related neurological risk factors did not contribute incrementally to the 
prediction of neuropsychological functioning above and beyond treatment 
intensity levels (PNORTI). 
The high level of agreement between raters of differing training 
backgrounds and specialties highlights the potential feasibility and clinical utility 
of the NPS and PNORTI in treatment settings with this population. Given the 
multitude of specialized care-providers involved in the diagnosis, treatment, 
management, assessment, and rehabilitation of childhood brain tumor patients, it 
is critical that providers are able to communicate efficiently to coordinate care. 
The NPS and PNORTI afford clinicians a simple and easy way to communicate 
rating of a child’s treatment intensity history and experience of treatment-related 
neurological comorbidities.  Our experience in this study suggests that these 
scales can be readily and reliability generated by practitioners with differing 
specialization backgrounds familiar with neuro-oncology treatments. 
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Furthermore, these scales are not time- or cost-prohibitive to generate and can be 
feasibility calculated within the context of a brief clinical visit and/or at discharge. 
Contrary to hypotheses, the NPS and PNORTI did not predict 
neuropsychological functioning approximately nine months following tumor-
directed treatments. These findings are largely consistent with literature on 
neuropsychological late effects in youth treated for brain tumors in childhood 
when interpreted within the context of the subacute survivorship period that was 
assessed. The extant literature suggests that neuropsychological late effects do not 
typically emerge or become clinically pronounced until several years post-
treatment (Gragert & Ris, 2011; Maddrey et al., 2005; Turner et al., 2009), 
thought to reflect damage to the developing nervous system in response to tumor-
directed treatments and neurological comorbidities (Merchant et al., 2008; 
Reddick et al., 2005; Reimers et al., 2003; Strother et al., 2001; Yeates, Ris, 
Taylor, & Pennington, 2009). Youth in the present study were assessed within 
nine months following tumor-directed treatments, potentially predating significant 
underlying neuroanatomical changes giving rise to neuropsychological late 
effects. 
Few studies have focused on the subacute period of survivorship. In 
previous longitudinal studies examining survivors pre-treatment, or in the post-
acute period following treatment, neuropsychological functioning was found to be 
broadly age-appropriate (Palmer at al., 2013; Ris et al., 2001), with measurable 
declines not noted until approximately one year later (Maddrey et al., 2005; 
Mulhern & Butler, 2004). That is, scores can be expected to remain relatively 
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stable and grossly intact within the first few months following treatment. In fact, 
Baseline and Follow-up performance for youth in the present study do not differ 
significantly, and were in the Average range at both timepoints. Because the 
present study was designed to assess changes in functioning between these 
timepoints, the lack of significant associations between NPS or PNORTI scores 
and Follow-up performance is likely impacted in part by the stability in 
performance. Statistically speaking, Baseline performance accounted for the vast 
majority of variance in Follow-up performance, with little additional variance 
available to be accounted for by treatment intensity or neurological risk factors. 
Importantly, it should be noted that those at highest risk for declines (i.e., greatest 
treatment intensity) were lost to Follow-up, thus skewing the sample towards 
those with greater medical and cognitive stability over time. 
However, there was a notable trend suggesting a relationship between 
greater treatment intensity and declines in neuropsychological functioning 
between Baseline and Follow-up. Significant associations between Baseline and 
Follow-up performances were noted for those with Low Intensity treatment 
histories (PNORTI), but not for those with Level 2 Intensity treatments. These 
findings suggest that neuropsychological functioning may be more stable across 
the subacute survivorship period for those with less intensive treatments, though 
performances for both groups remained within the Average range overall. 
However, these findings should be interpreted with caution given the small 
sample size and limited power of the present study. Future research is needed to 
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replicate these findings within a larger and representative sample of survivors 
with a range of treatment intensity histories. 
Neurological comorbidities and risk factors were also found to not account 
for a significant amount of additional variance in subacute neuropsychological 
performance above-and-beyond Baseline performance and treatment intensity 
levels. However, it should be noted that significant negative correlations were 
observed between overall neurological comorbidities and Baseline auditory 
attention and auditory memory measures. That is, exposure to a greater number of 
neurological comorbidities (e.g., hydrocephalus, antiepileptic medication, stroke, 
hormone dysfunction) was associated with worse auditory attention and auditory 
memory in the post-acute period. These results are consistent with previous 
studies that have documented the deleterious effects of multiple neurosurgical 
procedures (Kao et al., 1994; Ward et al., 2009), hydrocephalus (Mabbott et al., 
2005; Merchant et al., 2004; Stargatt, Rosenfeld, Maixner, & Ashley, 2007), post-
operative seizures and antiepileptic medication (Klein et al., 2003; van Breemen 
et al., 2007), on acute and post-acute neuropsychological functioning in childhood 
brain tumor survivors. Practitioners assessing neuropsychological functioning in 
this acute/post-acute period should be mindful of the impact that neurological 
comorbidities may play in neurocognitive functioning at this stage of 
survivorship. However, the influence of neurological comorbidities and risks is 
not strictly limited to the acute period, and may impact both long-term 
neurocognitive (Ater et al., 1996; Maddrey et al., 2005) as well as medical 
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outcomes (Antunes, 2001; Packer et al., 2003). As such, these factors are also 
important to consider through long-term care and follow-up.  
Taken together, the present study may have prematurely assessed for the 
emergence of neurocognitive deficits and their relation to treatment factors. Prior 
studies have established the clinical utility of the NPS for predicting long-term 
neuropsychological outcomes across domains of global intellectual functioning 
(Micklewright et al., 2008), attention, working memory, executive function, 
processing speed (McCurdy, Rane, Daly, & Jacobson, 2016; Taiwo, Na, & King, 
2016), and adaptive functioning (Papazoglou et al., 2009). However, these studies 
were conducted with survivors of childhood brain tumor several years (M = 2.42 – 
3.25) post-treatment (McCurdy, Rane, Daly, & Jacobson, 2016; Micklewright et 
al., 2008; Papazoglou, King, Morris, & Krawiecki, 2008), rather than those in the 
subacute period examined in the current study. These findings underscore the 
importance of timing when establishing the clinical utility of treatment intensity 
quantification scales in this population. 
Findings from the current study must be interpreted within the context of 
several statistical and methodological limitations. Given the exploratory nature of 
the present study, several analyses were conducted without statistical corrections 
for multiple comparisons. The lack of statistical correction for family-wise error 
rates significantly increases the likelihood of Type I error. The relatively small 
sample size in the present study also limited power to detect meaningful effects. It 
is also important to consider the relative distribution of PNORTI scores across the 
sample. Participant PNORTI scores were highly skewed towards Level 1 (n = 29) 
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compared to Level 2 (n = 6), with no participants receiving a Level 3 treatment 
intensity score. This uneven distribution in scores, restricted variability, and small 
cell size, may hinder the interpretation and generalizability of study findings 
(Hayes, 2013). Furthermore, it is feasible that those with higher NPS and 
PNORTI scores are at greater risk for relapse or death, introducing a potential 
confound biasing the present sample towards those with lower risk for adverse 
outcomes. In fact, individuals who completed Baseline assessments but were lost 
to Follow-up had significantly higher PNORTI scores compared with those who 
remained enrolled. 
The present study highlights the need for additional research examining 
the clinical utility of clinician-generated treatment intensity scales, particularly 
measures that are sensitive to early declines in neurocognitive functioning in the 
subacute period. Potential directions for future research include establishing a 
timeframe for the detection of neuropsychological late effects with the NPS and 
PNORTI. The present study provides the first evidence that these scales may not 
offer utility for predicting neuropsychological functioning nine months post 
tumor-directed treatment exposure. However, longitudinal research with proactive 
serial neuropsychological follow-ups may allow for a fine-grained determination 
of when neurocognitive impairments can be detected with these scales and the 
potential rate of decline as children transition into survivorship. Early 
identification may assist practitioners with selecting appropriate intervention 
efforts and preparing families for the potential need for future rehabilitation and 
accommodation services. Early intervention and long term care and follow-up is 
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essential, particularly for those at greatest risk for experiencing medical and 
neuropsychological late effects following treatment (Han et al., 2009).  
Additional research is also needed to establish the relationship between 
these treatment and risk quantification scales and underlying neuroanatomical 
changes. Namely, the NPS is purported to be a proxy for underlying neural tissue 
pathology (Micklewright et al., 2008; Ris et al., 2005), though this claim has yet 
to be verified in the literature. Researchers may consider incorporating structural 
and functional magnetic resonance imaging (MRI) into longitudinal research 
designs, specifically assessing for changes in white matter integrity and their 
relation to cognitive and adaptive functioning. Future research should also aim to 
establish the utility of the NPS and PNORTI for predicting those at greatest risk 
for relapse or death. The ability to identify children at greatest risk for disease 
recurrence or death has obvious clinical relevance in terms of routine monitoring, 
and may also assist researchers conducting longitudinal studies to estimate 
potential rates of attrition. 
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Participant Demographics 
  
Table 1. Participant Demographics 
    
 M (SD) Range n (%) 
Age (years) 11.00 (2.71) 6 – 15  
Age at diagnosis 9.50 (3.26) 0 – 15  
Time since 
diagnosis 
1.44 (1.88) 0.09 – 9.98  
Time since 
treatment 
0.23 (0.11) 0.09 – 0.64  
    
Sex    
     Male   17 (48.60%) 
     Female   18 (51.40%) 
Ethnicity    
     Caucasian   30 (85.70%) 
     African 
American 
  4 (11.40%) 
     Unknown   1 (2.90%) 
    
Note. Ages and times since diagnosis/treatment are presented in years. 
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Diagnoses & Treatment Histories 
 
 
Table 2. Diagnoses & Treatment Histories 
  
Diagnosis n % 
Low grade astrocytoma 10 28.60% 
Low grade glioma 8 22.90% 
Ependymoma 4 11.40% 
Ganglioglioma 4 11.40% 
Medulloblastoma 3 8.60% 
Germ cell tumor 3 8.60% 
Craniopharyngioma 1 2.90% 
Meningioma 1 2.90% 
Neurocytoma 1 2.90% 
   
Treatment & Neurological History   
Surgical Intervention   
     None 2 5.70% 
     Biopsy only 2 5.70% 
     Surgical resection 31 88.57% 
          1 surgery 25 71.40% 
          >1 surgery 6 17.10% 
Chemotherapy   
     None 24 68.60% 
     Chemotherapy 11 31.40% 
Radiotherapy   
     None 19 54.30% 
     Focal 10 28.60% 
     Cranial/ Craniospinal 1 2.90% 
     Craniospinal + Boost 5 14.30% 
Neurological Comorbidities   
     None 8 22.86% 
     Endocrine/hormone dysfunction 10 28.60% 
     Hydrocephalus 14 40.00% 
     Seizure prophylaxis 9 25.70% 
     Stroke 2 5.70% 
   
Note. N = 35.  
McCurdy, 69 
 
 
 
Baseline & Follow-Up Performance Descriptives 
 
Table 3. Baseline & Follow-up Performance Descriptives 
 
 Baseline  Follow-up    
 M SD  M SD  p d 
WASI-II FSIQ-2 98.39 17.04  -- --  -- -- 
WISC-IV PSI 93.06 19.29  92.49 20.67  .76 0.03 
WISC-IV DSF 9.00 3.51  9.09 3.069  .95 -0.03 
WISC-IV DSB 9.31 3.29  9.03 2.76  .55 0.09 
TEA-Ch CC Acc. 10.28 3.39  9.94 3.60  .76 0.10 
WRAML-2 SM-DFR 10.62 2.91  10.89 2.81  .37 -0.09 
BRIEF GEC 49.32 9.50  49.51 7.41  .83 -0.02 
BASC-2 ASC 51.91 10.52  52.03 9.03  .94 -0.01 
         
Note. PSI = Processing Speed Index; DSF = Digit Span Forward; DSB = Digit Span Backward; CC Acc. = 
Creature Counting Accuracy; SM-DFR = Story Memory-Delayed Free Recall; GEC = Global Executive 
Composite; ASC = Adaptive Skills Composite. 
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Neurological Predictor Scale: Hierarchical Regressions 
 
Table 4. Neurological Predictor Scale: Hierarchical Regressions 
 
 Model 1  Model 2 
 B SEB β  B SEB β 
WISC-IV PSI        
     Constant 19.81 10.63   29.37* 12.72  
     Baseline PSI 0.79** 0.11 0.78  0.76** 0.11 0.75 
     NPS     -1.39 1.04 -0.15 
        
F  50.43**    26.71**  
R2  0.61    0.63  
R2Δ  --    0.02  
f2  1.56    1.70  
f2Δ  --    0.05  
        
WISC-IV DSF        
     Constant 3.69** 1.08   4.75** 1.69  
     Baseline DSF 0.60** 0.11 0.69  0.56** 0.12 0.65 
     NPS     -0.16 0.20 -0.11 
        
F  28.98**    14.67**  
R2  0.48    0.49  
R2Δ  --    0.01  
f2  0.92    0.96  
f2Δ  --    0.02  
        
WISC-IV DSB        
     Constant 5.33** 1.28   5.41** 1.78  
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     Baseline DSB 0.40** 0.13 0.48  0.39* 0.13 0.48 
     NPS     -0.01 0.21 -0.01 
        
F  9.45**    4.58*  
R2  0.23    0.23  
R2Δ  --    <0.01  
f2  0.30    0.30  
f2Δ  --    0.00  
        
TEA-Ch CC Acc.        
     Constant 3.48* 1.58   4.39 2.17  
     Baseline CC Acc. 0.67** 0.15 0.65  0.65** 0.15 0.63 
     NPS     -0.15 0.24 -0.09 
        
F  20.86**    10.40**  
R2  0.42    0.43  
R2Δ  --    0.01  
f2  0.72    0.75  
f2Δ  --    0.02  
        
WRAML-2 SM-DFR        
     Constant 2.73* 1.18   2.04 1.69  
     Baseline DFR 0.77** 0.11 0.79  0.80** 0.12 0.81 
     NPS     0.10 0.16 0.07 
        
F  52.02**    25.64**  
R2  0.62    0.62  
R2Δ  --    <0.01  
f2  1.63    1.63  
f2Δ  --    0.00  
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BRIEF GEC        
     Constant 27.57** 5.20   25.49** 5.44  
     Baseline GEC 0.44** 0.10 0.60  0.42** 0.10 0.58 
     NPS     0.58 0.48 0.17 
        
F  17.67**    9.71**  
R2  0.36    0.39  
R2Δ  --    0.03  
f2  0.56    0.64  
f2Δ  --    0.05  
        
BASC-2 ASC        
     Constant 23.01** 6.00   19.36** 6.68  
     Baseline Adaptive 0.56** 0.11 0.65  0.57** 0.11 0.66 
     NPS     0.70 0.57 0.16 
        
F  24.33**    13.07**  
R2  0.42    0.45  
R2Δ  --    0.03  
f2  0.72    0.82  
f2Δ  --    0.05  
        
Note. In all hierarchical regressions, the Baseline score of the dependent variable of interest was 
entered into the first step (Model 1 = Baseline Performance), followed by NPS scores in the second 
step (Model 2 = Baseline Performance + NPS). NPS = Neurological Predictor Scale; PSI = Processing 
Speed Index; DSF = Digit Span Forward; DSB = Digit Span Backward; CC Acc. = Creature Counting 
Accuracy; SM-DFR = Story Memory-Delayed Free Recall; GEC = Global Executive Composite; ASC 
= Adaptive Skills Composite; * = p ≤ .05; ** = p ≤ .01. 
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Pediatric Neuro-Oncology Rating of Treatment Intensity & Neurological Risks: Hierarchical Regressions 
Table 5. Pediatric Neuro-Oncology Rating of Treatment Intensity & Neurological Risks: Hierarchical Regressions 
 
 Model 1  Model 2  Model 3 
 B SEB β  B SEB β  B SEB β 
WISC-IV PSI            
     Constant 19.81 10.63   27.95* 12.99   29.51* 13.56  
     Baseline PSI 0.79* 0.11 0.78  0.78** 0.11 0.77  0.77** 0.12 0.76 
     PNORTI     -6.05 5.58 -0.12  -5.27 5.89 -0.10 
     Neurological Risk         -1.38 2.90 -0.06 
            
F  50.43**    25.94**    16.94**  
R2  0.61    0.63    0.63  
R2Δ  --    0.01    <0.01  
f2  1.56    1.70    1.70  
f2Δ  --    0.05    0.00  
            
WISC-IV DSF            
     Constant 3.69** 1.08   5.23** 1.67   6.04** 1.85  
     Baseline DSF 0.60** 0.11 0.69  0.58** 0.11 0.68  0.53** 0.12 0.62 
     PNORTI     -1.21 1.01 -0.15  -0.95 1.05 -0.12 
     Neurological Risk         -0.56 0.55 -0.15 
            
F  28.98**    15.40**    10.62**  
R2  0.48    0.50    0.52  
R2Δ  --    0.02    0.02  
f2  0.92    1.00    1.08  
f2Δ  --    0.04    0.04  
            
WISC-IV DSB            
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     Constant 5.33** 1.28   6.23** 1.80   5.84** 1.97  
     Baseline DSB 0.40** 0.13 0.48  0.40** 0.13 0.48  0.42** 0.14 0.51 
     PNORTI     -0.80 1.12 -0.11  -0.98 1.18 -0.14 
     Neurological Risk         0.31 0.60 0.09 
            
F  9.45**    4.90**    3.28*  
R2  0.23    0.24    0.25  
R2Δ  --    0.01    0.01  
f2  0.30    0.32    0.33  
f2Δ  --    0.01    0.01  
            
TEA-Ch CC Acc.            
     Constant 3.48* 1.58   4.00 2.28   4.53 2.43  
     Baseline CC Acc. 0.67** 0.15 0.65  0.67** 0.15 0.64  0.65** 0.16 0.62 
     PNORTI     -0.40 1.26 -0.05  -0.17 1.32 -0.02 
     Neurological Risk         -0.45 0.68 -0.10 
            
F  20.86**    10.16**    6.79**  
R2  0.42    0.42    0.43  
R2Δ  --    <0.01    0.01  
f2  0.72    0.72    0.75  
f2Δ  --    0.00    0.02  
            
WRAML-2 SM-DFR            
     Constant 2.73* 1.18   2.22 1.68   1.80 1.88  
     Baseline DFR 0.77** 0.11 0.79  0.78** 0.11 0.80  0.81** 0.12 0.82 
     PNORTI     0.36 0.83 0.05  0.23 0.87 0.03 
     Neurological Risk         0.26 0.50 0.07 
            
F  52.02**    25.44**    16.66**  
R2  0.62    0.62    0.63  
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R2Δ  --    <0.01    <0.01  
f2  1.63    1.63    1.70  
f2Δ  --    0.00    0.03  
            
BRIEF GEC            
     Constant 27.57** 5.20   24.52** 5.99   24.39** 6.10  
     Baseline GEC 0.44** 0.10 0.60  0.43** 0.10 0.60  0.43** 0.10 0.59 
     PNORTI     2.59 2.54 0.14  2.40 2.67 0.13 
     Neurological Risk         0.37 1.33 0.04 
            
F  17.67**    9.37**    6.08**  
R2  0.36    0.38    0.38  
R2Δ  --    0.02    <0.01  
f2  0.56    0.61    0.61  
f2Δ  --    0.03    0.00  
            
BASC-2 ASC            
     Constant 23.01 6.00   22.79 6.95   21.53 6.78  
     Baseline Adaptive 0.56 0.11 0.65  0.56 0.11 0.65  0.56 0.11 0.65 
     PNORTI     0.21 3.17 0.01  -1.27 3.20 -0.05 
     Neurological Risk         2.64 1.53 0.23 
            
F  24.33**    11.80**    9.34**  
R2  0.42    0.42    0.48  
R2Δ  --    <0.01    0.05  
f2  0.72    0.72    0.92  
f2Δ  --    0.00    0.12  
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Note. In all hierarchical regressions, the Baseline score of the dependent variable of interest was entered into the first 
step (Model 1 = Baseline Performance), followed by PNORTI scores in the second step (Model 2 = Baseline 
Performance + PNORTI), and the sum of neurological risk factors in the third step (Model 3 = Baseline Performance 
+ PNORTI + Neurological Risk). PNORTI = Pediatric Neuro-Oncology Rating of Treatment Intensity; PSI = 
Processing Speed Index; DSF = Digit Span Forward; DSB = Digit Span Backward; CC Acc. = Creature Counting 
Accuracy; SM-DFR = Story Memory-Delayed Free Recall; GEC = Global Executive Composite; ASC = Adaptive 
Skills Composite; * = p ≤ .05; ** = p ≤ .01. 
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Participant Recruitment & Enrollment Flow Diagram 
 
Recruitment  
Assessed for Eligibility  
(n = 496) 
 
 
      
      
     Excluded (n = 422) 
      Ineligible (n = 394) 
      Other reasons (n = 28) 
      
     Declined (n = 24) 
      Lack of interest (n = 11) 
      Passive refusal (n = 10) 
      Time constraints (n = 2) 
      
      
Enrollment  
Enrolled  
(n = 50) 
 
 
      
      
Baseline  
Completed Baseline Assessment  
(n = 50) 
 
 
      
      
     Lost to Follow-Up (n = 15) 
      Passive refusal (n = 5) 
      Tumor Recurrence (n = 5) 
      Active Withdrawal (n = 2) 
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      Deceased (n = 2) 
      Relocation (n = 1) 
      
      
Follow-Up  
Completed Follow-Up Assessment  
(n = 35) 
 
 
      
      
Analysis  
Included in Analyses 
(n = 35) 
 
 
 
 
 
 
 
Figure 1. Participant recruitment and enrollment flow diagram.  
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Neuropsychological Performance by Treatment Intensity Level 
PNORTI Level 1: 
PNORTI Level 2: 
Figure 2. Baseline and Follow-up performances for survivors who received Level 1 and 
Level 2 intensity treatments (PNORTI). All scores have been converted to standard scores (M 
= 100; SD = 15). Higher scores reflect better performance for all measures except for the 
GEC, where higher scores reflect worse executive functioning. PSI = Processing Speed Index; 
DSF = Digit Span Forward; DSB = Digit Span Backward; CC Acc. = Creature Counting 
Accuracy; SM-DFR = Story Memory-Delayed Free Recall; GEC = Global Executive 
Composite; ASC = Adaptive Skills Composite.  
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Appendix A: Neurological Predictor Scale (NPS) 
 
 
 
Neurological Predictor Scale (NPS) 
 
Neurological Predictor Scale Instructions: Circle the number that corresponds 
to the statement that best describes the child’s exposure to the conditions or 
treatments listed in each of the four sections. Please read all possible options, 
and choose only one response in each section. 
  
1. Circle the answer below that describes the child’s experience: 
  
0 = Child has not been diagnosed with any neurological conditions other 
than brain tumor. 
1 = Child has been diagnosed with a hormone deficiency. 
2 = Child has been prescribed seizure medications or has been diagnosed 
with hydrocephalus. 
3 = Child has been diagnosed with hydrocephalus and a hormone 
deficiency. 
3 = Child has been prescribed seizure medications and diagnosed with a 
hormone deficiency.  
4 = Child has been prescribed seizure medications and diagnosed with 
hydrocephalus. (May or may not also have a hormone deficiency). 
  
2. Circle the answer below that describes the child’s brain tumor surgery. 
Please do not include hydrocephalus/shunt insertion surgeries in this 
section: 
  
0 = Child did not undergo surgery to remove his/her brain tumor. 
1 = Child underwent biopsy/biopsies only; he/she did not have any other 
surgery. 
2 = Child underwent one neurosurgery related to the removal of his/her 
brain tumor. Child did not undergo a second surgery. 
3 = Child underwent more than one surgery related to the removal of his/her 
brain tumor. 
  
3. Circle the answer below that describes the child’s radiation treatment: 
  
0 = Child did not undergo radiation treatment of any kind. 
1 = Child only received focal radiation or radiation at the site of his/her 
tumor. 
2 = Child received whole-brain or craniospinal radiation. 
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3 = Child received both whole-brain radiation and focal radiation (a 
“boost”) at the site of the tumor. 
  
4. Circle the answer below that describes the child’s course of 
chemotherapy: 
  
0 = Child did not receive chemotherapy of any kind. 
1 = Child received chemotherapy as part of his/her treatment.  
  
  
_____   Total Score 
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Appendix B: Pediatric Neuro-Oncology Rating of Treatment Intensity 
(PNORTI) 
 
 
Pediatric Neuro-Oncology Rating of Treatment Intensity (PNORTI) 
Directions: Please review carefully the criteria at the bottom of the page that lists 
examples of treatment modalities under each of the three levels of intensity. The 
intensity levels of chemotherapy regimens that are subsumed under the overall 
levels of treatment intensity are described at the bottom.  Based on the 
information regarding each patient’s treatment, use the criteria at the bottom of 
this page to circle one number to indicate the intensity of treatment (1, 2, 3).  
Make your ratings based on the specified criteria, rather than your own clinical 
judgment. 
    
Overall Treatment Intensity Levels* 
Level 1 
Surgical resection only (biopsy does not qualify) 
AND/OR 
Focal radiation 
AND/OR 
Low Intensity chemotherapy** 
Level 2 
Cranial or Craniospinal radiation with or without Medium or less Intensity 
chemotherapy** 
OR 
Medium Intensity chemotherapy** 
Level 3 
High Intensity chemotherapy** with or without craniospinal radiation 
* In cases of relapse, please evaluate the entire treatment history when 
making the rating. 
** See description of chemotherapy intensity levels below. 
 
Chemotherapy Intensity Levels 
Low 
Any outpatient chemotherapy 
Medium 
Any inpatient chemotherapy regimen 
**DOES NOT include chemotherapy regimens listed in High Intensity 
chemotherapy** 
High 
High-dose chemotherapy + stem cell rescue 
OR 
Cumulative doxorubicin dose ≥ 300mg/m2 
OR 
Doses of methotrexate (1g/m2 or above) that require leucovorin rescue 
  
